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The most common cause of malignant distal biliary obstruction is pancreatic cancer, as 70–90% of patients will develop jaundice during the course of their
disease. Pancreatic cancer is usually advanced at presentation, and curative resection is possible in < 15% of patients. If a patient is to undergo early
surgical resection, biliary drainage is not prerequisite. Early surgery without preoperative biliary drainage does not increase the risk of complications, as
compared with preoperative biliary drainage, followed by surgery. Postoperative complications do not differ signiﬁcantly between the two approaches. In
light of no signiﬁcant improvements in patient survival in large trials of a surgery-ﬁrst followed by adjuvant therapy over the past 2 decades, there has
been a shift towards preoperative neoadjuvant chemotherapy in the setting of borderline resectable disease. Consequently, effective preoperative biliary
drainage has become a paramount concern in this setting. Multiple retrospective and prospective studies have compared the outcomes between covered
metal stents and uncovered metal stents in malignant biliary obstruction. In patients undergoing neoadjuvant chemoradiation or surgical resection, no
signiﬁcant self-expanding metal stent-related complications or adverse events were seen. Additionally, no signiﬁcant difference in overall survival was
seen between the two groups. Within the palliative realm, self-expanding metal stents have also become the stent of choice with greater duration of
patency. In an effort to deliver a survival beneﬁt, there are many ongoing trials and developments in the realm of the therapeutic endoscopy. In this
review, we will examine what we have accomplished and further explore the potential beneﬁts of endoscopic interventions on the horizon.
Copyright  2015, Society of Gastrointestinal Intervention. Published by Elsevier.
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Malignant biliary strictures most commonly arise from either
pancreatic cancer or cholangiocarcinoma. Often the ﬁrst presen-
tation of these cancers is with jaundice and biliary obstruction.
Unfortunately most of these also present in the late stages of the
disease. The most recent Surveillance, Epidemiology, and End Re-
sults data show the overall 5-year survival rate of pancreatic cancer
at 6–7%. If detected early with only local disease (reported as
approximately 10% of cases), the survival rates are better but still
abysmal at approximately 25%.1 Similarly, the 5-year survival with
extrahepatic biliary cancer after resection was approximately 30%
but 0% in those cases that were unresectable.2 Given these sobering
statistics, the goal with early stage disease is to proceed to therapy
in an efﬁcient and timely manner, speciﬁcally to get to surgical
resection, as this is the only hope for cure. Palliative therapy by
contrast focuses on relief of symptoms and delay of disease
progression.
This review discusses the rationale for screening high risk pa-
tients, the diagnosis ofmalignant strictures, the endoscopic therapy
currently available for these strictures, and possible future thera-
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Approximately 10–20% of pancreatic cancers may have an un-
derlying genetic predisposition.3,4 Although screening would not
be appropriate for the general population, consideration of
screening in high-risk individuals may be useful if a highly sensitive
and cost-effective test is identiﬁed. Groups with known genetic
syndromes that predispose them to an increased risk of pancreatic
cancer are most likely to beneﬁt from screening. The highest risk
patients include those with Peutz–Jeghers syndrome (STK11/ LKB1
mutation), familial atypical multiple molemelanoma (p16/CDKN2A
mutation), Lynch syndrome (MLH1, MSH2, MSH6, and PMS2 mu-
tations), hereditary breast and ovarian cancer syndrome (BRCA1/2
mutations), and hereditary pancreatitis (PRSS1 mutation). Addi-
tionally those with a strong family history of pancreatic cancer
(familial pancreatic cancer) may also be appropriate for screening.
Those patients with three or more ﬁrst-degree relatives are at a 32-
fold increased lifetime risk of pancreatic cancer. Mutations in PALB2
have been associated with familial pancreatic cancer.3
Multiple studies have assessed imaging modalities for screening
of pancreatic cancer.3,5 A large study across ﬁve United States in-
stitutions compared computed tomography (CT), magnetic reso-, USA
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asymptomatic high-risk adults and showed that EUS was the best
modality to detect a pancreatic abnormality (11%, 33.3%, and 42.6%
respectively).6 Currently there are no speciﬁc guidelines as to how
to screen and what age to start this process, but EUS or MRI seems
to be the best currently available modality for early detection in
these high risk patients.
Development of new technology for better screening for
pancreatic cancer is needed. Evaluation of optical markers in the
periampullary duodenum with low-coherence enhanced back-
scattering has been reported to discriminate between healthy
controls and patients with pancreatic adenocarcinoma with 95%
sensitivity, 71% speciﬁcity, and 85% area under the receiver oper-
ator characteristic curve. Additionally these numbers were not
affected when looking speciﬁcally at resectable stage disease.7
Further study is underway to better elucidate the utility of this
technology and assess whether it may be a promising technique for
screening.
Diagnosis
Distinguishing between malignant and benign strictures in an
efﬁcient manner may portend a better chance for cure for local
disease but also for those patients with borderline resectable dis-
ease. Imaging studies as well as stricture sampling provide com-
plementary information regarding both the etiology of the stricture
but also the extent of disease.
Multiple imaging modalities have been studied to assess the
best method of detection and differentiation between malignant
and benign strictures.
A prospective study assessing magnetic resonance chol-
angiopancreatography (MRCP) compared to CT, endoscopic retro-
grade cholangiopancreatography (ERCP), and percutaneous
transhepatic cholangiography for the diagnosis of malignant biliary
strictures versus benign strictures showed comparable sensitivities
and speciﬁcities for ERCP versus MRCP (sensitivity 85% for both and
speciﬁcity of 75% for ERCP and 71% for MRCP). CT had lower
sensitivity and speciﬁcity compared to both ERCP and MRCP.8
Although MRCP was comparable, ERCP provides the ability to
sample the stricture as discussed below, which maymake it a more
attractive study despite the invasiveness of the test.
The sensitivity and speciﬁcity of ﬂudeoxyglucose-positron
emission tomography (18FDG-PET) to distinguish malignant from
benign strictures has varied widely across studies and for different
anatomic locations (intrahepatic versus perihilar versus extrahe-
patic). In one study of 93 patients with cholangiocarcinoma un-
dergoing preoperative 18FDG-PET scans, the sensitivity and
speciﬁcity for intrahepatic versus extrahepatic lesions was 95% and
100% versus 69.2% and 66.7% respectively.9 An additional study
comparing 18FDG-PET with conventional imaging modalities (CT
and MRI) showed no statistically signiﬁcant advantage in favor of
18FDG-PET for diagnosis but did show higher accuracy over CT in
the diagnosis of regional and distant metastases, suggesting that
18FDG-PET should be an adjunct to other modalities for staging
purposes.10 The use of 18FDG-PET for not only diagnosis but also
staging and follow-up for cholangiocarcinoma has been reviewed
separately beyond the details above.11
Studies on the yield of biliary brushings during ERCP have
shown a wide range of sensitivities from approximately 30% to
60%.12 Performing multiple brushings has been shown to increase
sensitivity, and after three consecutive negative brushings, the
probably of malignancy is very low.13 Sensitivity does not seem to
increase with dilation.14 Improvement in sensitivities with some of
these methods is thought to be related to disruption of the biliary
epithelium, yielding better access to malignant cells.Studies of results with endobiliary forceps biopsies have shown
increased sensitivities, on average around 60%, but this method is
time consuming and technically difﬁcult and therefore not used on
a routine basis.12
In a prospective comparison of ERCP with biopsies or brushings
and EUS-guided ﬁne needle aspiration (FNA) in patients with both
biliary and pancreatic pathology, ERCP-based techniques were su-
perior for the subgroup with biliary tumors (ERCP 75% vs. EUS 25%),
and EUS-FNA guided biopsy was better in the subgroup with
pancreatic masses (EUS 60% vs. ERCP 38%).15 A more recent study
published in Gastrointestinal Endoscopy in July 2014 compared EUS-
guided FNA to ERCP tissue sampling with brushings and forceps
biopsy. This was a prospective, single-blinded trial of same session
EUS and ERCP for malignant biliary strictures. The overall sensi-
tivity and accuracy was 94% and 94% respectively for EUS compared
to 50% and 53% for ERCP sampling. This study also conﬁrmed
comparable sensitivity for biliary masses but superior sensitivity
for EUS-FNA over ERCP in strictures related to pancreatic masses.16
FNA needle size has been investigated to determine sample
adequacy. A meta-analysis of 22-gauge needles versus 25-gauge
needles for FNA of solid pancreatic masses showed that 25-gauge
needles were more sensitive than 22-gauge needles for the diag-
nosis of malignancy (93% versus 85%).17 In another study, the 25-
gauge needles were again superior over 22-gauge but also over
19-gauge Trucut core biopsy needles as well.18 Additional core bi-
opsy needles have been developed as well. A 22-gauge core needle
in one small study did not show superior diagnostic results over the
22-gauge FNA needle.19 Most recently a 25-gauge core biopsy
needlewas studied and produced high sensitivities on each of three
passes (83%, 91%, and 96%) despite low histological core biopsy
yields (32%).20 Randomized studies comparing the 25-gauge core
needles and standard FNA needles are needed.
Finally, the combination of sampling methods appears to in-
crease the yield of diagnosis. A study of 133 patients undergoing
ERCP for jaundice underwent trimodal tissue sampling by brushing,
endobiliary forceps biopsy, and ﬁne-needle aspiration cytology. 104
patients had a malignant stricture with (46 pancreatic, 30 chol-
angiocarcinoma, 13 ampullary, and 15 metastatic). The highest
yield of sampling regardless of type was seen with ampullary
cancers. The combination of techniques was superior to any one
alone.21
Despite the investigation of numerous adjunctive tests to
routine cytology and histology, only ﬂuorescence in-situ hybridi-
zation (FISH) has seen consistently optimistic results. This tech-
nique uses ﬂuorescently labeled DNA probes to assess for polysomy
on certain predetermined chromosomal loci. In a study by Fritcher
et al,22 498 brushings from pancreaticobiliary strictures were
assessed with FISH versus routine cytology. The sensitivity of pol-
ysomy FISH was 42.9%, which was signiﬁcantly higher than routine
cytology (20.1%). Speciﬁcity approached 100% for both.22 Additional
studies have conﬁrmed this result and in fact exceeded the sensi-
tivity value.23–25 Given these ﬁndings, the use of FISH in the setting
of negative or indeterminate routine cytology has been recom-
mended in recent guidelines by The Papanicolaou Society of
Cytopathology.26
Endoscopic therapy
Stenting
Previously it was thought that preoperative drainage was
beneﬁcial as, theoretically, drainage was thought to decrease
complications related to cholestasis including cholangitis, impaired
clotting and immunological response, and fat malabsorption.
Despite lack of evidence for it,27 preoperative drainage has been
Fig. 1. The algorithm for management of malignant distal biliary obstruction.
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tients. However, if a patient is to undergo early surgical resection
for resectable pancreatic cancer, biliary drainage is not necessary. In
2010 a randomized, multicenter trial was done to compare pre-
operative biliary drainage with plastic stenting for 4–6 weeks
versus early surgery (within 1 week) in patients with resectable
pancreatic cancer. Serious complications occurred in 39% of the
early surgery group versus 74% of the biliary drainage group.
Cholangitis and stent related complications were the main com-
plications in the biliary drainage group.28 There were a number of
criticisms with the paper including a high rate of initial ERCP failure
(25%) and excessively high ERCP complication rate (46%).29
Throughout the past 2 decades, the approach of an operation
ﬁrst, followed by adjuvant therapy failed to show any signiﬁcant
improvements in patient survival. Over the past 6 years, there has
been a shift towards preoperative neoadjuvant chemotherapy and
radiation in the setting of borderline resectable disease (Table 1).30–
34 Neoadjuvant therapy efﬁciently delivers early treatment of
micrometastic disease. Although the longer preoperative interval
was not associated with local tumor progression during the pre-
operative therapy, it required durable biliary decompression.
Consequently, effective preoperative biliary drainage has become a
paramount concern in this setting.
Additionally, the use of plastic stents in for biliary drainage in
this setting has also become less desirable as self-expandable
metallic stents (SEMS) have been shown to be superior as far as
rates of occlusion and cholangitis with minimal intra- or post-
operative complications.35,36
SEMS have also been shown to be better than plastic stents for
palliative stenting as well. A Cochrane database review evaluated
nine studies that compared the stent materials. This showed a risk
ratio for recurrent biliary obstruction of 0.48, favoring metal overTable 1 Summary of Trials of Preoperative Chemoradiation for Resectable Pancreat
Study No. of patients Preoperative regimen
Evans et al (1992)34 28 5-FU þ XRT 50.4 Gy
Pisters et al (1998)32 35 5-FU þ XRT 30 Gy
Pisters et al (2002)33 37 Paclitaxel þ XRT 30 Gy
Evans et al (2008)31 86 Gem þ XRT 30 Gy
Varadhachary et al (2008)30 90 Gem/Cis then Gem þ XRT 30 G
5-FU, ﬂuorouracil; Cis, cisplatin Gem, gemcitabine; XRT, radiotherapy.plastic stents.37 Further studies compared types of SEMSdcovered
versus partially covered versus fully covered. The majority of these
studies have shown no differences between these stents as far as
time to recurrent obstruction (Table 2).38–46
In patients undergoing neoadjuvant chemoradiation or surgical
resection, no signiﬁcant SEMS-related complications or adverse
events were seen, and no signiﬁcant difference in overall survival
was seen between the covered and uncovered metal stent
groups.38–40
In these studies, covered SEMS were more frequently associated
with migration and uncovered SEMS were more frequently asso-
ciated with tumor ingrowth.38–40
Metal stents have been associated with higher rates of post-
ERCP pancreatitis compared to plastic stents.47 The frequency be-
tween covered and uncovered stents has shown mixed results in
studies with either similar pancreatitis rates or increased rates with
covered stents.39,47 Additionally, the rate of acute cholecystitis has
been higher with the covered stents than uncovered.40,48,49
These studies clearly suggest that metal stents are superior over
plastic stents but comparison of covered versus uncovered stents
has been difﬁcult. Comparison across studies has been challenging
due to the use of different brands of stents with different metal
struts and coatings. Additional controlled randomized studies are
needed to assess the newer stents for time to recurrent obstruction
and rates of complications. Taking into consideration the issues
discussed above, the algorithm for management of malignant distal
biliary obstruction is shown in Fig. 1.
Finally, given the success of drug eluding stents in the vascular
arena, a natural transition would be to utilize this technology with
biliary stents if a suitable drug could be identiﬁed. Intravenous
paclitaxel in combination with gemcitabine is considered ﬁrst line
therapy for metastatic pancreatic cancer. Additionally, paclitaxelic Cancer
Resection
rate (%)
% r1 Median survival
resected patients (mo)
Local recurrence
rate (%)
61 d 18 d
57 10 25 10
54 32 19 d
75 12 34 11
y 58 4 31 25
Table 2 Sample of Selected Comparative Studies of Covered Versus Uncovered Self-expandable Metallic Stents (SEMS)
Study SEMS used % with recurrent
obstruction
Patency rates (%) Time to recurrent
obstruction (mo)
Adverse Events
Lee et al (2013)39 Zilver/Flexxus/
Niti-S/Wallstent/
Wallﬂex
U: 38
C: 35
d U: 26.3
C: 15.4
U: 1% migration; 1% cholecystitis; 1%
pancreatitis; 5% cholangitis
C: 7% migration; 0% cholecystitis; 6%
pancreatitis; 2% cholangitis
Li et al (2012)45 Nitinol U: 64
C: 51
U: 85, 68, 43
C: 86, 83, 60
(3 mo, 6 mo, 12 mo)
U: 5.3
C: 8.4
U: 0% migration; 0% cholecystitis; 11%
cholangitis; 2% pancreatitis
C: 9% migration; 3% cholecystitis; 20%
cholangitis; 3% pancreatitis
Kawakubo et al
(2011)46
Wallstent/ComVi/
Diamond/
Wallﬂex/JOSTENT SelfX/
SMART/ZEO
U: 38
C: 11
U: 77, 58, 29
C: 94, 82, 73
(3 mo, 6 mo, 12 mo)
U: 3.7
C: 7.4
U: 0% migration; 5% cholecystitis; 0%
pancreatitis; 0% cholangitis
C: 4% migration, 0% cholecystitis; 14%
pancreatitis; 7% cholangitis
Telford et al
(2010)40
Wallstent U: 18
PC: 29
d U: 23.4
PC: 11.7
U: 0% migration; 2% pancreatitis, 7%
cholecystitis
PC: 12% migration, 0% pancreatitis; 7%
cholecystitis
Kullman et al
(2010)38
Nitinol U: 23
C: 24
U: 97, 87, 78, 56
C: 95, 83, 74, 50
(1 mo, 3 mo, 6 mo, 12 mo)
U: 6.5
C: 5.0
(25% stents occluded)
U: 0% migration; 1% cholecystitis; 2%
pancreatitis; 6% cholangitis
C: 3% migration; 1% cholecystitis; 1.5%
pancreatitis; 4% cholangitis
Gwon et al
(2010)44
Nitinol/Zilver/Sentinol U: 33
PC: 12
U: 98, 83, 72, 57, 57
PC: 98, 98, 91, 76, 76
(1 mo, 3 mo, 6 mo, 9 mo,
12 mo)
U: 5.6
C: 4.9
U: 0% migration; 0% cholecystitis
PC: 3% migration; 2% cholecystitis
Yoon et al
(2006)41
Wallstent U: 37
C: 25
U: 83, 66, 54, 36
C: 83, 78, 67, 54
(100 d, 200 d, 300 d,
400 d)
U: 10.4
C: 13.0
U: 2% migration; 0% cholecystitis; 0%
pancreatitis
C: 8% migration; 3% cholecystitis; 0%
pancreatitis
Park et al
(2006)42
Wallstent U: 19
C: 21
U: 92, 77, 54, 37
C: 92, 72, 56, 37
(1 mo, 3 mo, 6 mo,
12 mo)
U: 4.7
C: 4.9
U: 0% migration; 1% cholecystitis; 2%
pancreatitis
C: 6% migration; 1% cholecystitis; 6%
pancreatitis
Isayama et al
(2004)43
Diamond stents U: 38
C: 14
U: 81, 68, 55
C: 100, 91, 74
(3 mo, 6 mo, 12 mo)
U: 5.5
C: 10.0
U: 0% cholecystitis; 2% pancreatitis
C: 4% cholecysitits; 9% pancreatitis
C, covered; PC, partially covered U, uncovered.
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models pertinent to stent reocclusion and tumor ingrowth.50 Given
the above, local drug therapy with paclitaxel within biliary stents
may provide improved rates of stent patency. This has been eval-
uated in limited human studies. In a prospective, randomized pilot
study out of South Korea, 52 patients were randomizedd26 to drug
eluting stents and 26 to covered metal stents as the control group.
Forty-nine patients were included in the ﬁnal analysis (24 in
intervention group and 25 in the control group). Although study
size was a limitation, stent patency duration and survival timewere
not signiﬁcantly different between the two groups.51 Further larger
studies of this drug may be warranted or additional drug investi-
gation may prove more fruitful to lower the rates of reocclusion.Ablation
Radiofrequency ablation (RFA) has been an established treat-
ment for malignant or premalignant conditions such as Barrett’s
esophagus and hepatocellular carcinoma. Endobiliary RFA has been
studied as a palliative adjunct to biliary stenting in patients with
unresectable disease to decrease the rate of tumor ingrowth and
epithelial hyperplasia within the stent. One initial study showed
promising results with excellent 90-day patency rates (18 of 21
patients had patent stents) as well as an excellent safety proﬁle. All
treated patients received uncovered metal stents post RFA treat-
ment.52 Further study has conﬁrmed safety of this treatment and
additionally showed a signiﬁcant increase in post treatment bile
duct diameter. All treated patients again underwent stent place-
ment post RFA (6 plastic, 13 partially or fully covered metal, and 1uncovered metal). Choledochoscopy conﬁrmed coagulation ne-
crosis in three patients.53 Although these studies of small pop-
ulations suggest potential beneﬁt with this treatment, further
larger randomized studies are needed to document meaningful
utility and, particularly, safety.Injection therapy
Although theoretically encouraging, improvement in outcomes
with injection of antitumor therapy or placement of radioactive
seeds, speciﬁcally for pancreatic cancer, has unfortunately been
disappointing despite proven administration safety. Potential in-
jection treatments have attempted stimulation of the immune
system with lymphocyte culture, tumor necrosis factor-a, or den-
dritic cells, use of viruses, or local administration of chemothera-
peutic agents or radioactive therapy.
Injection of allogenic mixed lymphocyte culture (Cytoimplant)
directly into the tumor causes release of cytokines and induction of
tumor regression. One small Phase I study with eight participants
had two patients with partial responses and one with a minor
response, and there was no correlation with survival.54
TNFeradeBiologic is an adenovector that expresses human
tumor necrosis factor-a under the control of a promotor inducible
by chemoradiation. A small randomized trial of TNFerade with
standard of care (ﬂuorouracil combined with radiotherapy) versus
standard of care alone in patients with locally advanced pancreatic
cancer showed a longer median survival (14.7 months vs. 11.1
months) in the treatment group.55 The ﬁnal results of the multi-
center trial were reportedly not as encouraging.56
Lisa Cassani and Jeffrey H. Lee / Management of malignant distal biliary obstruction 19ONYX-015 is an adenovirus that preferentially replicates in and
kills malignant cells. In a Phase I study with injection under CT
guidance, treatment with the virus was well tolerated with only
one patient having mild pancreatitis.57 In a subsequent Phase II/III
study with injection under EUS guidance, no objective responses
were seen with ONYX-015 alone and only a partial response in two
patients when given in combination with gemcitabine. Serious
complications were seen including sepsis and duodenal
perforation.58
Injection with tumor antigen-loaded dendritic cells is another
possible therapy. These dendritic cells stimulate the immune
response as antigen presenting cells. A small pilot study with seven
patients with unresectable pancreatic cancer had three of seven
patients with mixed responses. The injections were well tolerated
without toxicity.59 An additional small study of ﬁve patients com-
bined intravenous gemcitabine with dendritic cell endoscopic in-
jection. Three of the ﬁve patients had responses, one with partial
remission and two with stable disease for > 6 months. Again, there
were no adverse events.60
Gemcitabine injection is a natural transition from the standard
of care intravenous treatment well established as standard of care
for advanced pancreatic cancer. A trial from the Mayo Clinic
enrolled 36 patients with locally advanced or metastatic pancreatic
cancer. The injection of chemotherapy was well tolerated with no
Grade 3 or higher adverse events. Three of the 20 patients alive at
the end of the study had been downstaged from unresectable to R0
resection. Survival at 6 months and 1 year was 76% and 46%,
respectively.61 However, the true beneﬁt of local injection therapy
could not be discerned in the midst of systemic chemotherapy.
Radioactive brachytherapy with 125I may be a synergistic ther-
apy in combination with chemotherapy for treatment of unre-
sectable pancreatic cancer. A prospective study of 100 cases
combined implantation of radioactive seeds followed by intrave-
nous gemcitabine therapy to assess overall survival, progression-
free survival and additional therapeutic effects. Pain scores
measured by the visual analog scale improved after 1 week post
implantation but overall and progression-free survival were not
different.62
Overall intratumoral injection has failed to provide overtly
encouraging results. Further studies with different therapeutic
targets are needed to call injection therapy a successful modality.
Multidisciplinary approach
The management of malignant biliary strictures requires a
multidisciplinary team approach including gastroenterologists,
surgical oncologists, and medical oncologists. Aggressive therapy
with early stage disease can lead to better outcomes, but there is a
lot of room for improvement going forward. Detection of cancer
with new screening modalities and developing more accurate
diagnostic techniques hopefully will shift the 5-year survival rate
towards the other end of the spectrum.
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